Radioimmunotherapy of Lymphoma: Bexxar and Zevalin
Section snippets
B Cells and B-Cell Lymphoma
Non-Hodgkin's lymphomas are also broadly classified as either B-cell lymphomas or T-cell lymphomas, based on their lineage. B cells arise from reticuloendothelial elements in the prenatal liver and spleen, whereas T cells arise from the thymus. Because B cells evolve from the stem cell to mature lymphocytes and plasma cells, they express a variety of specific antigens that are characteristic of specific cell types. The expression of these epitopes varies as the cell matures and takes on
Radioimmunotherapy of B-Cell Lymphoma
This review deals with the basic issues involved in the development, the practical nuclear medicine aspects, and the clinical efficacy of 2 radiolabeled immunotherapeutic products, Bexxar and Zevalin, for the treatment of low-grade follicular B-cell lymphomas that are refractory or relapsed after treatment with the current best practice. These products are the first radiolabeled antibody regimen approved in the United States for the treatment of tumors. When specific issues are addressed, they
B-Cell Antigens
CD20 is one of many epitopes expressed on the mature B cell. Because it is so frequently expressed, it was selected early as a target for the development of monoclonal antibody therapy. Epitopes are protein components of cells that usually have a defined function and a distinct molecular configuration. For example, CD20 functions as a transmembrane calcium channel and is frequently expressed on both B cells and B-cell tumors. As stated earlier, CD20 appears as the B cell is maturing within the
Generic Issues: Bexxar and Zevalin
Currently, 2 radiolabeled antibodies are available for treatment of follicular low-grade non-Hodgkin's lymphoma, Bexxar and Zevalin. Bexxar contains 131I-labeled tositumomab, and Zevalin contains 90Y-labeled ibrutumomab. In both cases, the radiolabeled component is a murine anti-CD20 monoclonal antibody and in both cases, an unlabeled antibody is infused before the radiolabeled component is infused. The immunoreactivity of the 2 anti-CD20 murine monoclonal antibodies is not identical, but it is
Clinical Efficacy: RIT of Lymphoma
There are an abundance of clinical studies that demonstrate the efficacy of RIT of follicular low-grade non-Hodgkin's lymphoma. The initial and, at the time of this writing, current approval of both Bexxar and Zevalin was based on results in patients who were either refractory to, or relapsed after, rituximab therapy. Since that time, the use of rituximab has broadened considerably, and it is now used in many ways: as maintenance therapy after remission postchemotherapy, as an initial solo
Conclusions
Bexxar and Zevalin are approved by regulatory agencies, government, and private health insurance companies in the United States and Canada for the treatment of patients with follicular, low-grade non-Hodgkin's lymphoma. They produce significant improvement, sometimes with no evidence of disease (CR) for many months to several years. Other patients, with PRs, also remain symptom-free for long periods. The regimen were initially approved in patients who had relapsed or were refractory to previous
Acknowledgments
The author expresses gratitude and appreciation to colleagues present and past: Morton Coleman, MD, John Leonard, MD, Shankar Vallabhajosula, PhD, Vasilios Avlonitis, RPh, Zubaida Rahman, RPh, and Lale Kostakoglu, MD for their support during the period in which we worked together to understand and improve the principles and practice of radioimmunotherapy and to make this therapy available to patients with non-Hodgkin's lymphoma.
References (18)
- et al.
Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature
Clin Lymphoma
(2004) - et al.
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
J Clin Oncol
(2000) - et al.
Continuous cultures of fused cells secreting antibody of predefined specificity
Nature
(1975) - et al.
Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides
J Nucl Med
(1995) - et al.
Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: Implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma
Cancer Invest
(2003) - et al.
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution
Cancer Biother Radiopharm
(2009) Tositumomab and 131I therapy in non-Hodgkin's lymphoma
J Nucl Med
(2002)- et al.
Outpatient treatment with 131I-anti-B1 antibody: Radiation exposure to family members
J Nucl Med
(2001) - et al.
Bexxar radioimmunotherapy can be safely administered by healthcare professionals with minimal whole body exposure
J Nucl Med
(2003)
Cited by (127)
Drug discovery
2023, Translational Radiation OncologyNuclear medicine therapy of lung cancer, breast cancer and colorectal cancer
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4Monoclonal antibody based radiopharmaceuticals for imaging and therapy
2021, Current Problems in CancerCitation Excerpt :The first clinical trial of mAb-based therapeutic radiopharmaceuticals can be dated back to 1988 against non-Hodgkin's lymphoma (NHL)3. Only 90Y-ibritumomab tiuxetan, the FDA approved drug, is still actively used for therapeutic purposes4. Initial progress of RIT has been hampered by the fact that the first generation of radiolabeled mAbs were of murine origin with potential of triggering a human antimouse antibody (HAMA) response if used repeatedly in humans.
Delivery of radioimmunotherapy for solid tumors
2021, Systemic Drug Delivery Strategies: Volume 2 of Delivery Strategies and Engineering Technologies in Cancer ImmunotherapyTargeted Radionuclide Therapy: A Historical and Personal Review
2020, Seminars in Nuclear MedicineCitation Excerpt :Furthermore, if disrupted, the metal moiety is less likely to be water soluble and hence will not wash out from the site where it was initially deposited. Accordingly, a 90Y-labeled anti-CD 20 immunoglobulin, 90Y was developed and also evaluated in clinical trials.23 When 90Y was used as the therapeutic radionuclide, it became necessary to identify a radioisotope of another element with a γ emission and chemical properties similar to 90Y in order to reliably detect the biodistribution externally and to image if desired.
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344
2019, International Journal of Radiation Oncology Biology Physics